AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie shares rose 4% to a record high after the company secured a settlement extending generic competition protection for its blockbuster immunology drug, Rinvoq, until April 2037, a four-year extension from prior expectations. This development is critical for AbbVie, which is pivoting to immunology assets like Rinvoq and Skyrizi to offset revenue declines from its once top-selling drug Humira, now facing biosimilar competition. Analysts view the extension as a significant positive, providing a key growth driver with additional runway and potentially adding approximately $2 billion to Rinvoq's peak-year sales, bolstering AbbVie's long-term revenue outlook.

Analysis

AbbVie (ABBV) shares surged 4% to a record high following the announcement of a legal settlement that extends the market exclusivity for its blockbuster drug, Rinvoq. This agreement delays generic competition until April 2037, a significant four-year extension compared to prior analyst expectations of 2033. This development is strategically critical as AbbVie navigates the revenue erosion from its former top-seller Humira, which began facing biosimilar competition in 2023. The extension solidifies Rinvoq's role as a primary growth driver, de-risking the company's long-term financial outlook. Rinvoq already accounts for over 10% of total revenue, with $5.97 billion in 2024 sales, and analysts now project the extended exclusivity could add approximately $2 billion to its peak-year sales. According to J.P. Morgan, this provides AbbVie with a longer runway to develop its experimental pipeline ahead of the next major loss of exclusivity in the mid-2030s, reinforcing the company's guidance for its two key immunology treatments, Skyrizi and Rinvoq, to collectively generate over $31 billion in revenue by 2027.

Key Decisions for Investors

• Investors should revise their financial models for AbbVie to incorporate the four-year extension of Rinvoq's exclusivity to 2037, which materially improves the company's long-term revenue and cash flow projections.
• While the news de-risks the medium-term growth profile, focus should remain on the progress of AbbVie's clinical pipeline and Rinvoq's label expansion trials, as these are critical for ensuring growth beyond the newly extended patent cliff.
• Given the stock's immediate surge to a record high, investors should assess whether the improved long-term fundamentals are fully priced in at current levels before initiating or adding to positions.